Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment

Myocardial infarction (MI) is a cardiovascular disease (CVD) with high morbidity and mortality worldwide, which is a serious threat to human life and health. Inflammatory and immune responses are initiated immediately after MI, and unbalanced inflammation post-MI can lead to cardiac dysfunction, sca...

Full description

Saved in:
Bibliographic Details
Main Authors: Wenyuan Zhang, Dan Peng, Shiqi Cheng, Rui Ni, Meiyang Yang, Yongqing Cai, Jianhong Chen, Fang Liu, Yao Liu
Format: Article
Language:English
Published: MDPI AG 2025-02-01
Series:Bioengineering
Subjects:
Online Access:https://www.mdpi.com/2306-5354/12/2/205
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850081970473664512
author Wenyuan Zhang
Dan Peng
Shiqi Cheng
Rui Ni
Meiyang Yang
Yongqing Cai
Jianhong Chen
Fang Liu
Yao Liu
author_facet Wenyuan Zhang
Dan Peng
Shiqi Cheng
Rui Ni
Meiyang Yang
Yongqing Cai
Jianhong Chen
Fang Liu
Yao Liu
author_sort Wenyuan Zhang
collection DOAJ
description Myocardial infarction (MI) is a cardiovascular disease (CVD) with high morbidity and mortality worldwide, which is a serious threat to human life and health. Inflammatory and immune responses are initiated immediately after MI, and unbalanced inflammation post-MI can lead to cardiac dysfunction, scarring, and ventricular remodeling, emphasizing the critical need for an effective inflammation-regulating treatment. With the development of novel therapies, the drug delivery system specific to inflammatory cells offers significant potential. In this review, we introduce immune cells and fibroblasts involved in the development of MI and summarize the newly developed delivery systems related to the use of injectable hydrogels, cardiac patches, nanoparticles, and extracellular vesicles (EVs). Finally, we highlight the recent trends in the use of inflammatory cell-targeting drug delivery systems involving different strategies that facilitate the effective treatment of MI.
format Article
id doaj-art-d6480a7545e14aabab8f8929cbce0bd2
institution DOAJ
issn 2306-5354
language English
publishDate 2025-02-01
publisher MDPI AG
record_format Article
series Bioengineering
spelling doaj-art-d6480a7545e14aabab8f8929cbce0bd22025-08-20T02:44:36ZengMDPI AGBioengineering2306-53542025-02-0112220510.3390/bioengineering12020205Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction TreatmentWenyuan Zhang0Dan Peng1Shiqi Cheng2Rui Ni3Meiyang Yang4Yongqing Cai5Jianhong Chen6Fang Liu7Yao Liu8Department of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaDepartment of Pharmacy, Daping Hospital, Army Medical University, Chongqing 400042, ChinaMyocardial infarction (MI) is a cardiovascular disease (CVD) with high morbidity and mortality worldwide, which is a serious threat to human life and health. Inflammatory and immune responses are initiated immediately after MI, and unbalanced inflammation post-MI can lead to cardiac dysfunction, scarring, and ventricular remodeling, emphasizing the critical need for an effective inflammation-regulating treatment. With the development of novel therapies, the drug delivery system specific to inflammatory cells offers significant potential. In this review, we introduce immune cells and fibroblasts involved in the development of MI and summarize the newly developed delivery systems related to the use of injectable hydrogels, cardiac patches, nanoparticles, and extracellular vesicles (EVs). Finally, we highlight the recent trends in the use of inflammatory cell-targeting drug delivery systems involving different strategies that facilitate the effective treatment of MI.https://www.mdpi.com/2306-5354/12/2/205inflammationimmune cellsfibroblastsdelivery systemmyocardial infarction
spellingShingle Wenyuan Zhang
Dan Peng
Shiqi Cheng
Rui Ni
Meiyang Yang
Yongqing Cai
Jianhong Chen
Fang Liu
Yao Liu
Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment
Bioengineering
inflammation
immune cells
fibroblasts
delivery system
myocardial infarction
title Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment
title_full Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment
title_fullStr Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment
title_full_unstemmed Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment
title_short Inflammatory Cell-Targeted Delivery Systems for Myocardial Infarction Treatment
title_sort inflammatory cell targeted delivery systems for myocardial infarction treatment
topic inflammation
immune cells
fibroblasts
delivery system
myocardial infarction
url https://www.mdpi.com/2306-5354/12/2/205
work_keys_str_mv AT wenyuanzhang inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT danpeng inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT shiqicheng inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT ruini inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT meiyangyang inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT yongqingcai inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT jianhongchen inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT fangliu inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment
AT yaoliu inflammatorycelltargeteddeliverysystemsformyocardialinfarctiontreatment